Study questions certain breast cancer treatment

November 09, 2017 04:54 AM

Patients with estrogen receptor positive breast cancer typically are treated with either tamoxifen or aromatase inhibitors for five years after their cancer treatment finishes.

But a new study suggests that may not be long enough. Researchers at the University of Michigan looked at women with ER positive breast cancer. They found those who originally had large tumors had up to a 40 percent chance of a recurrence 20 years later.

Advertisement – Content Continues Below

Experts say it could indicate patients might need to stay on tamoxifen or other medication longer than five years.


WNYT Staff

Copyright 2017 - WNYT-TV, LLC A Hubbard Broadcasting Company

Relay Media Amp
Watchful eyes remain on looming flood threat

Loudonville woman accused of stealing $30,000 from trusted friend

Special elections are set to fill 11 vacant seats at the State Capitol

Adams man pleads not guilty in deadly hit-and-run

Hudson Falls teen admits to role in deadly crash